Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.7300 (-0.14%) ($10.7300 - $10.7300) on Fri. Mar. 12, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.02% (three month average) | RSI | 35 | Latest Price | $10.7300(-0.14%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.6% a day on average for past five trading days. | Weekly Trend | FOLD declines -6.5% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(58%) IWO(54%) XBI(52%) IWM(51%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -2.51% in a week (0% probabilities). VIXM(-30%) VXX(-15%) UUP(-12%) UNG(-6%) TLT(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.51% (StdDev 5.02%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.44(-122.74%) | Inflection Point | Yes | Resistance Level | $11.34 | 5 Day Moving Average | $10.47(2.48%) | 10 Day Moving Average | $10.66(0.66%) | 20 Day Moving Average | $11.34(-5.38%) | To recent high | -56.9% | To recent low | 6.3% | Market Cap | $2.771b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |